GlaxoSmithKline heart drug misses goal in major study [ BeritaTerkini ]

<div id="yom-ad-LREC" class="yom-ad yom-ad-LREC"> <center> <div id="yom-ad-LREC-iframe" class="yom-ad"></div> </center> </div> <p><br></p> <div class="body-slot-container"> <div class="body-slot-mod"> <div class="yom-remote"> <div class="yom-loading" id="mediacontentrelatedstory_container"></div> </div> </div> </div> <p>LONDON (Reuters) – An experimental drug from GlaxoSmithKline, designed to fight heart disease in a new way, failed to meet its main goal in the first of two big late-stage clinical studies, the company said on Tuesday.</p> <p>Darapladib did, however, produce greater reductions in serious coronary events in some of the pre-defined secondary endpoints that GSK said required further analysis.</p> <p>The once-daily pill, which is designed to prevent heart attacks and strokes by fighting clogged arteries in a completely different way from cholesterol-lowering drugs, has been viewed by analysts as a high-risk project.</p> <p>(Reporting by Ben Hirschler)</p> <ul id="topics" class="hidden"> <li>Health</li> <li>Pharmaceuticals & Drug Trials</li> <li>GlaxoSmithKline</li> <li>experimental drug</li> <li>heart attacks</li> </ul><p></p> //<!--[CDATA[ jQuery(".gmframe").load(function (){jQuery(this).remove();}); //]]--> <br><br>

GlaxoSmithKline heart drug misses goal in major study [ BeritaTerkini ]

LONDON (Reuters) – An experimental drug from GlaxoSmithKline, designed to fight heart disease in a new way, failed to meet its main goal in the first of two big late-stage clinical studies, the company said on Tuesday. Dara…

Read more »